吸入糖皮质激素改善极早产儿肺功能(PICSI):随机双盲安慰剂对照试验
PICSI试验在澳大利亚珀斯儿童医院纳入170名6-12岁极早产(<32周)儿童,随机接受丙酸氟替卡松125μg或安慰剂每日两次共12周。结论认为整体肺功能改善幅度有限,未来需考虑个体表型及其他药物。
要点
- 极早产儿童吸入丙酸氟替卡松12周后FEV1 Z评分有轻度改善。
- 治疗组3例因哮喘样症状加重停药,安慰剂组1例因不耐受停药。
- 整体改善幅度有限,提示需按肺病表型个体化治疗。
核心结论
- 作为整体,极早产儿童接受吸入糖皮质激素治疗12周后肺功能仅轻度改善。
研究设计与样本
- PICSI为在澳大利亚珀斯儿童医院开展的随机、双盲、安慰剂对照试验。
- 纳入170名6-12岁、出生<32周的极早产儿童,随机1:1接受丙酸氟替卡松125μg或安慰剂每日两次共12周。
- 主要结局为治疗12周后支气管舒张前FEV1变化,按意向性分析。
主要发现
- 吸入糖皮质激素组83例中3例因不良事件(哮喘样症状加重)需停药,安慰剂组87例中1例因不良事件(头晕、头痛、腹痛及皮肤状况恶化无法耐受)需停药。
关键数值与推荐
- 纳入标准:6-12岁、出生<32周,无严重先天异常、心肺缺陷、神经发育障碍、糖尿病或近3个月内使用糖皮质激素。
- 干预:丙酸氟替卡松125μg或安慰剂每日两次,共12周。
- 主要结局:治疗12周后支气管舒张前FEV1变化。
临床怎么用
- 对极早产儿童使用吸入糖皮质激素12周仅带来轻度肺功能改善,需权衡获益与个体不良反应风险。
- 临床管理应考虑早产后肺病的个体表型,而非对所有极早产儿童统一使用吸入糖皮质激素。
局限性
- 31例(18%)在12周前中止治疗,多数因COVID-19疫情影响。
- 研究仅评估12周治疗,未报告更长疗程或远期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the substantial burden of lung disease throughout childhood in children who were born very preterm, there are no evidence-based interventions to improve lung health beyond the neonatal period. We tested the hypothesis that inhaled corticosteroid improves lung function in this population. METHODS: PICSI was a randomised, double-blind, placebo-controlled trial at Perth Children's Hospital (Perth, WA, Australia) to assess whether fluticasone propionate, an inhaled corticosteroid, improves lung function in children who had been born very preterm (<32 weeks of gestation). Eligible children were aged 6-12 years and did not have severe congenital abnormalities, cardiopulmonary defects, neurodevelopmental impairment, diabetes, or any glucocorticoid use within the preceding 3 months. Participants were randomly assigned (1:1) to receive 125 μg fluticasone propionate or placebo twice daily for 12 weeks. Participants were stratified for sex, age, bronchopulmonary dysplasia diagnosis, and recent respiratory symptoms using the biased-coin minimisation technique. The primary outcome was change in pre-bronchodilator forced expiratory volume in 1 s (FEV1) after 12 weeks of treatment. Data were analysed by intention-to-treat (ie, all participants who were randomly assigned and took at least the tolerance dose of the drug). All participants were included in the safety analyses. This trial is registered at the Australian and New Zealand Clinical Trials Registry, number 12618000781246. FINDINGS: Between Oct 23, 2018, and Feb 4, 2022, 170 participants were randomly assigned and received at least the tolerance dose (83 received placebo and 87 received inhaled corticosteroid). 92 (54%) participants were male and 78 (46%) were female. 31 participants discontinued treatment before 12 weeks (14 in the placebo group and 17 in the inhaled corticosteroid group), mostly due to the impact of the COVID-19 pandemic. When analysed by intention-to-treat, the change in pre-bronchodilator FEV1 Z score over 12 weeks was -0·11 (95% CI -0·21 to 0·00) in the placebo group and 0·20 (0·11 to 0·30) in the inhaled corticosteroid group (imputed mean difference 0·30, 0·15-0·45). Three of 83 participants in the inhaled corticosteroid group had adverse events requiring treatment discontinuation (exacerbation of asthma-like symptoms). One of 87 participants in the placebo group had an adverse event requiring treatment discontinuation (inability to tolerate the treatment with dizziness, headaches, stomach pains, and worsening of a skin condition). INTERPRETATION: As a group, children born very preterm have only modestly improved lung function when treated with inhaled corticosteroid for 12 weeks. Future studies should consider individual phenotypes of lung disease after preterm birth and other agents to improve management of prematurity-associated lung disease. FUNDING: Australian National Health and Medical Research Council, Telethon Kids Institute, and Curtin University.
引用
- Urs RC, Evans DJ, Bradshaw TK, et al. Inhaled corticosteroids to improve lung function in children (aged 6-12 years) who were born very preterm (PICSI): a randomised, double-blind, placebo-controlled trial. Lancet Child Adolesc Health. 2023. PMID: 37385269. doi:10.1016/S2352-4642(23)00128-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。